Originally published by Robert Kraft.
Reuters reported that the Food and Drug Administration has declined to approve Eagle Pharmaceutical Inc.’s Kangio (bivalirudin), a ready-to-use version of Angiomax (bivalirudin), a drug to prevent blood clots among patients undergoing heart surgery. Unlike Angiomax, Kangio did not need to be reconstituted with water and diluted before use. The FDA declined Kangio’s application in its current form and requested additional information from the drugmaker. The Bergen (NJ) Record also covered the story.
from Texas Bar Today http://ift.tt/1XA8nk5
via Abogado Aly Website